HELIXMITH CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,260 KRW | -3.40% |
|
-4.80% | -30.96% |
| Apr. 25 | Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in funding | CI |
| Feb. 05 | Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in funding | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Helixmith Co Ltd, formerly ViroMed Co Ltd, is a Korea-based company mainly engaged in the development and sales of natural medicines and health functional foods. The Company operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.
Sector
Food Processing
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.96% | 152M | |
| +8.20% | 7.78B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -13.13% | 3.44B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M | |
| -16.45% | 802M |
- Stock Market
- Equities
- A084990 Stock
- News Helixmith Co., Ltd
- Helixmith Stock Plummets Following Clinical Setback in Gene Therapy Candidate
